Research Roundup: What We're Reading this Week

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. Last week, BioVersys AG https://www.cidrap.umn.edu/antimicrobial-stewardship/partnership-aims-foster-development-drug-non-tb-mycobacteria announced a new agreement with Shionogi to jointly develop its novel drug for treating non-tuberculosis (TB) mycobacteria, which affects approximately 250,000 people per year, primarily in North America and Asia. Shionogi will provide $6.3 million as an upfront investment for the development of the drug candidate, BV500, through clinical studies and licensing. BioVersys has stated that the candidate has the potential to become a best-in-class therapeutic for non-TB mycobacteria infections, which are currently treated with a lengthy and complex regimen.Scientists at King’s College London have developed a new class of antifungal compounds that could lead to a promising new tool against Candida auris, a dangerous fungal pathogen and a growing global threat. The researchers modified an existing class of antifungal drugs called azoles (which can lose their effectiveness as C. auris becomes resistant to them) to be more impervious to resistance, an approach that has demonstrated promise in lab and preclinical studies. If the new antifungals continue to succeed in further preclinical studies, this research could pave the way for a new, first-in-class antifungal that continues to work in the face of resistance, helping reduce mortality and limit the spread of resistant strains of bacteria.A research team from the University of California, Riverside has made a significant advance in our basic understanding of the Plasmodium falciparum malaria parasite, a step toward the development of new and improved drugs for malaria. The researchers identified two key proteins within the parasite’s cells that control gene expression and used advanced genetic tools to reduce the expression of these proteins, which led to the death of the parasite, verifying their essential role and potential as a drug target. Crucially, these proteins also have no human counterparts. These findings help pinpoint essential targets for developing future drugs that are effective and have minimal side effects.

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. Newly published research suggests that a patient-centered approach, combining novel diagnostic tools with targeted therapies, could be a game changer in tuberculosis (TB) treatment. Current TB treatment requires a complicated, months-long regimen that can be hard for patients to adhere to, leading to treatment failure and the emergence of drug-resistant TB strains. The researchers behind the new study suggest that new diagnostic tools that can better distinguish between patients with less and more severe forms of TB combined with, respectively, shorter or longer, more resource-intensive treatment courses could improve patient outcomes, reduce the burden on health systems, and limit the emergence of drug resistance.Last week, Bavarian Nordic announced the start of the first of two clinical trials testing the use of its Jynneos mpox/smallpox vaccine in vulnerable populations, including infants and children two years old and younger and pregnant or breastfeeding women. If the vaccine demonstrates safety and efficacy, the trial data could help support expanded access to the vaccine for the most vulnerable populations. The trial is being led by the University of Antwerp and the University of Kinshasa and supported financially by EDCTP3 and the Coalition for Epidemic Preparedness Innovations.A recently published study found that a single-dose, long-lasting flu drug could provide protection for an entire flu season, offering longer and more effective protection than our current seasonal flu vaccines. The clinical trial followed 5,000 healthy adults for the entire duration of the most recent flu season, finding that the highest dose of the drug provided more than 76 percent protection compared with a placebo shot. The drug has also demonstrated efficacy against a wide variety of flu strains in a previous study in mice, compared to the season influenza vaccines, which are designed (prior to flu season based on expert assumptions) to protect against at least three of the seasonal strains that circulate each season and whose efficacy depends on how well they match the flu strains that end up circulating.